Viela Bio, Inc. Sustainability Profile
Viela Bio, Inc., a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in developing innovative therapies for autoimmune and inflammatory diseases. With a strong focus on monoclonal antibodies, Viela Bio's core products, including its flagship treatment, are designed to address unmet medical needs, setting them apart in a competitive market. The company operates primarily in North America and has made significant strides in clinical development, achieving key milestones that underscore its commitment to advancing patient care. Recognised for its scientific expertise and dedication to innovation, Viela Bio continues to enhance its market position, contributing to the evolving landscape of biopharmaceuticals.
DitchCarbon Score
How does Viela Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viela Bio, Inc.'s score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viela Bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for reporting. The company is a current subsidiary of Amgen Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship with Amgen Inc., Viela Bio may align with the sustainability initiatives and targets set by Amgen. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the level of Amgen Inc. While specific reduction targets or achievements for Viela Bio are not disclosed, the overarching commitments from Amgen Inc. may influence its climate strategy. Amgen has been actively working towards reducing its carbon footprint and enhancing sustainability practices across its operations. In summary, while direct emissions data for Viela Bio, Inc. is not available, the company is likely to be guided by the climate commitments and initiatives of its parent company, Amgen Inc., as part of its broader corporate sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 0,000,000,000 |
How Carbon Intensive is Viela Bio, Inc.'s Industry?
How Carbon Intensive is Viela Bio, Inc.'s Location?
Viela Bio, Inc.'s Scope 3 Categories Breakdown
Viela Bio, Inc.'s Scope 3 emissions, which increased by 814% last year and increased significantly since 2012, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 37% of Scope 3 emissions.
Top Scope 3 Categories
Viela Bio, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Viela Bio, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
